Announcement Information

Num| Date| Title| Submitter
10 2021.04.06 Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(혈액암 치료제) Aptabio Therapeutics Inc.
9 2021.03.30 Outcomes of Annual Meeting of Shareholders Aptabio Therapeutics Inc.
8 2021.03.24 Material Management Information related to Judgment of Investment(COVID-19 치료제 APX-115의 US FDA 2상 임상시험 IND 승인) Aptabio Therapeutics Inc.
7 2021.03.22 Submission of Audit Report Aptabio Therapeutics Inc.
6 2021.03.15 Reporting reasons for holding general shareholders' meeting on the most concentrated date Aptabio Therapeutics Inc.
5 2021.03.03 Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제) Aptabio Therapeutics Inc.
4 2021.01.29 Resolutions for Convocation of General Meeting of Shareholders Aptabio Therapeutics Inc.
3 2021.01.29 30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations) Aptabio Therapeutics Inc.
2 2020.12.31 Material Management Information related to Judgment of Investment(COVID-19 치료제 APX-115의 US FDA 2상 임상시험 IND 신청) Aptabio Therapeutics Inc.
1 2020.12.11 Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제(Therapeutic Agent For Liver Disorder)) Aptabio Therapeutics Inc.
2021.04.06 Aptabio Therapeutics Inc.
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(혈액암 치료제)
2021.03.30 Aptabio Therapeutics Inc.
Outcomes of Annual Meeting of Shareholders
2021.03.24 Aptabio Therapeutics Inc.
Material Management Information related to Judgment of Investment(COVID-19 치료제 APX-115의 US FDA 2상 임상시험 IND 승인)
2021.03.22 Aptabio Therapeutics Inc.
Submission of Audit Report
2021.03.15 Aptabio Therapeutics Inc.
Reporting reasons for holding general shareholders' meeting on the most concentrated date
2021.03.03 Aptabio Therapeutics Inc.
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제)
2021.01.29 Aptabio Therapeutics Inc.
Resolutions for Convocation of General Meeting of Shareholders
2021.01.29 Aptabio Therapeutics Inc.
30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations)
2020.12.31 Aptabio Therapeutics Inc.
Material Management Information related to Judgment of Investment(COVID-19 치료제 APX-115의 US FDA 2상 임상시험 IND 신청)
2020.12.11 Aptabio Therapeutics Inc.
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제(Therapeutic Agent For Liver Disorder))